Bicalutamide (CAS 90357-06-5) – Antineoplastic API

Bicalutamide (CAS 90357-06-5) is a high-potency non-steroidal antiandrogen antineoplastic API with a targeted mechanism of action. It competitively binds to androgen receptors in prostate tissue, blocking the stimulatory effect of androgens on cancer cell growth and proliferation. Produced under strict GMP guidelines, it ensures ultra-high purity, consistent bioactivity, and compliance with global pharmaceutical quality standards for oncology drugs.

This premium API is a core raw material for pharmaceutical manufacturers developing prostate cancer treatments. It is widely applied in formulating medications for advanced prostate cancer, often combined with luteinizing hormone-releasing hormone (LHRH) agonists to achieve comprehensive androgen deprivation therapy. With proven clinical efficacy in slowing disease progression and improving patient survival rates, it addresses the critical demand for effective prostate cancer therapies. For pharmaceutical R&D teams and production enterprises, it provides a trusted solution to advance targeted oncology treatments.